XML 78 R24.htm IDEA: XBRL DOCUMENT
v3.20.4

Other Consolidated Financial Statement Detail | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Other Consolidated Financial Statement Detail | Other Consolidated Financial Statement Detail Supplemental Cash Flow Information Supplemental disclosure of cash flow information for the years ended December 31, 2020, 2019 and 2018, is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Cash paid during the year for: |  |  |  |  |  |
Interest |  | $ | 272.7 |  |  | $ | 244.2 |  |  | $ | 243.2 |
Income taxes |  | 906.7 |  |  | 1,064.5 |  |  | 1,007.1 |
Non-cash Operating, Investing and Financing Activity In the fourth quarter of 2018 we accrued $300.0 million upon reaching $20.0 billion in total cumulative sales of FUMADERM and TECFIDERA (together, the Fumapharm Products), which was paid in the first quarter of 2019. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately $12.4 million and $50.0 million in our consolidated balance sheets as of December 31, 2020 and 2019, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 10, Property, Plant and Equipment, to these consolidated financial statements. Other Income (Expense), Net Components of other income (expense), net, are summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Interest income |  | $ | 42.0 |  |  | $ | 120.0 |  |  | $ | 112.5 |
Interest expense |  | (222.5) |  |  | (187.4) |  |  | (200.6) |
Gain (loss) on investments, net |  | 685.7 |  |  | 204.7 |  |  | 119.5 |
Foreign exchange gains (losses), net |  | (10.7) |  |  | (7.0) |  |  | (9.9) |
Other, net |  | 2.9 |  |  | (47.0) |  |  | (10.5) |
Total other income (expense), net |  | $ | 497.4 |  |  | $ | 83.3 |  |  | $ | 11.0 |
Gain (loss) on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. For the year ended December 31, 2020, net unrealized and realized gains on our holdings in equity securities were approximately $681.8 million and $12.1 million, respectively, compared to net unrealized and realized gains of $150.1 million and $50.0 million in 2019. The net unrealized gains recognized during the year ended December 31, 2020, primarily reflects an increase in the fair value of Denali and Sangamo common stock of approximately $703.9 million. The following table summarizes our gain (loss) on investments, net that relates to our equity securities held as of December 31, 2020, 2019 and 2018:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Net gains (losses) recognized during the period on equity securities |  | $ | 693.9 |  |  | $ | 200.1 |  |  | $ | 127.9 |
Less: Net gains (losses) recognized on equity securities sold during the period and on capital distributions |  | 12.1 |  |  | 50.0 |  |  | (0.6) |
Unrealized gains (losses) recognized during the period on equity securities |  | $ | 681.8 |  |  | $ | 150.1 |  |  | $ | 128.5 |
Accrued Expenses and Other Accrued expenses and other consists of the following:
|  | As of December 31,
(In millions) |  | 2020 |  | 2019
Revenue-related reserves for discounts and allowances |  | $ | 1,080.6 |  |  | $ | 1,001.1 |
Collaboration expenses |  | 389.9 |  |  | 281.6 |
Employee compensation and benefits |  | 333.8 |  |  | 309.1 |
Royalties and licensing fees |  | 218.5 |  |  | 220.9 |
Derivative liabilities |  | 181.5 |  |  | 6.7 |
Current portion of contingent consideration obligations |  | 149.6 |  |  | 148.4 |
Other |  | 791.4 |  |  | 798.0 |
Total accrued expenses and other |  | $ | 3,145.3 |  |  | $ | 2,765.8 |
Other Long-term Liabilities Other long-term liabilities were $1,329.6 million and $1,348.9 million as of December 31, 2020 and 2019, respectively, and include accrued income taxes totaling $709.9 million and $803.3 million, respectively.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration